Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Vatalinib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Vatalinib | DRUG | - |
Inclusion criteria * Healthy female * Surgically sterile or post-menopausal * At least a weight of 50 kg and have a body mass index (BMI) ≤33.0 * Non-smokers or those who smoke 25 cigarettes or less per day Exclusion criteria * Use of certain prescription and over the counter drugs * Having receive...
Vatalinib is an investigational small molecule being studied in healthy volunteers. It is not approved for any disease and is currently in Phase 1 clinical development. The only completed trial evaluated its use in healthy sterile or postmenopausal female volunteers, focusing on drug-drug interactions.
Vatalinib is being developed by Novartis AG, a multinational pharmaceutical company traded on the New York Stock Exchange under the ticker symbol NVS. The company is conducting clinical research to evaluate the drug's properties in early-stage trials.
Vatalinib is in Phase 1 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities. The single trial listed is a completed Phase 1 study, and the drug remains under investigation for potential future use.
Vatalinib has one completed clinical trial registered under NCT00426452. This Phase 1 study evaluated a 1250 mg oral dose of Vatalinib under fasting and fed conditions with a proton-pump inhibitor in healthy female volunteers. The trial enrolled 24 participants and was not blinded or controlled.
No, Vatalinib is not FDA approved. It is an investigational drug currently in Phase 1 clinical trials. The available data shows only one completed study in healthy volunteers, and the drug has not progressed to later-stage trials or regulatory submission.